Renovorx Inc (RNXT)

$1.02 -0.01 (-0.97%)
Market Cap 32.89M
Revenue (ttm) 40,000.00
Net Income (ttm) -8.81M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -22,025.00%
Debt to Equity Ratio 0.00
Volume 109,200
Avg Vol 154,662
Day's Range N/A - N/A
Shares Out 36.55M
Stochastic %K 93%
Beta 1.12
Analysts Strong Sell
Price Target $4.88

Latest News on RNXT

RenovoRx Increases U.S. Production of RenovoCath® Devices to Meet Growing Demand from Oncology Community

Apr 16, 2025, 8:30 AM EDT - 3 days ago

RenovoRx Increases U.S. Production of RenovoCath® Devices to Meet Growing Demand from Oncology Community

RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th

Apr 4, 2025, 8:30 AM EDT - 15 days ago

RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th

RenovoRx Reports Initial Revenues from RenovoCath® Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

Apr 1, 2025, 8:30 AM EDT - 18 days ago

RenovoRx Reports Initial Revenues from RenovoCath® Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting

Mar 28, 2025, 8:00 AM EDT - 22 days ago

RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting

RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting

Mar 26, 2025, 8:00 AM EDT - 24 days ago

RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting

RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12:00 p.m. ET

Mar 20, 2025, 8:00 AM EDT - 4 weeks ago

RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12:00 p.m. ET

RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025

Mar 19, 2025, 8:00 AM EDT - 4 weeks ago

RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025

RenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders

Feb 26, 2025, 8:00 AM EST - 7 weeks ago

RenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders

RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery

Feb 13, 2025, 8:00 AM EST - 2 months ago

RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery

RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock

Feb 11, 2025, 7:00 AM EST - 2 months ago

RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock

RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock

Feb 6, 2025, 8:49 PM EST - 2 months ago

RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock

RenovoRx Announces Proposed Public Offering

Feb 6, 2025, 4:05 PM EST - 2 months ago

RenovoRx Announces Proposed Public Offering

RenovoRx: From Clinical Promise To Commercial Reality And Trading At A Significant Discount

Feb 5, 2025, 2:14 AM EST - 2 months ago

RenovoRx: From Clinical Promise To Commercial Reality And Trading At A Significant Discount

RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025

Jan 27, 2025, 8:00 AM EST - 2 months ago

RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025

RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025

Jan 8, 2025, 8:00 AM EST - 3 months ago

RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025

RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform

Dec 30, 2024, 8:00 AM EST - 3 months ago

RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform

Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx's Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

Nov 20, 2024, 8:45 AM EST - 5 months ago

Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx's Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights

Nov 14, 2024, 8:00 AM EST - 5 months ago

RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights

RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians

Sep 25, 2024, 8:30 AM EDT - 7 months ago

RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians

RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer

Sep 19, 2024, 8:30 AM EDT - 7 months ago

RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 26th Annual Global Investment Conference on September 9, 2024 in New York

Aug 27, 2024, 8:30 AM EDT - 8 months ago

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 26th Annual Global Investment Conference on September 9, 2024 in New York

RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

Aug 14, 2024, 8:30 AM EDT - 8 months ago

RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

RenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist®

Jul 8, 2024, 8:30 AM EDT - 10 months ago

RenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist®

University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx's Pivotal Phase III TIGeR-PaC Clinical Trial

Jun 26, 2024, 8:30 AM EDT - 10 months ago

University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx's Pivotal Phase III TIGeR-PaC Clinical Trial

RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships

Jun 10, 2024, 8:30 AM EDT - 11 months ago

RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships

RenovoRx CEO Issues Update Letter to Shareholders

May 30, 2024, 8:30 AM EDT - 11 months ago

RenovoRx CEO Issues Update Letter to Shareholders

Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRx's TAMP™ Therapy Platform to Improve Targeted Cancer Drug Treatment Delivery

May 21, 2024, 9:00 AM EDT - 11 months ago

Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRx's TAMP™ Therapy Platform to Improve Targeted Cancer Drug Treatment Delivery

RenovoRx to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024

May 14, 2024, 9:00 AM EDT - 1 year ago

RenovoRx to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024

RenovoRx CEO Shaun R. Bagai to Present at the Aegis Capital Virtual Conference on May 9, 2024

May 2, 2024, 9:00 AM EDT - 1 year ago

RenovoRx CEO Shaun R. Bagai to Present at the Aegis Capital Virtual Conference on May 9, 2024

RenovoRx Regains Compliance with Nasdaq Stockholders' Equity Requirement

Apr 18, 2024, 8:30 AM EDT - 1 year ago

RenovoRx Regains Compliance with Nasdaq Stockholders' Equity Requirement

RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting

Apr 16, 2024, 8:30 AM EDT - 1 year ago

RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting

RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026

Apr 15, 2024, 8:00 AM EDT - 1 year ago

RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026

RenovoRx Announces $11.1 Million at Market Private Placement

Apr 8, 2024, 8:30 AM EDT - 1 year ago

RenovoRx Announces $11.1 Million at Market Private Placement

RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024

Apr 5, 2024, 8:30 AM EDT - 1 year ago

RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024

RenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024

Mar 12, 2024, 9:00 AM EDT - 1 year ago

RenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024

RenovoRx Highlights Key Leadership Promotions

Mar 8, 2024, 4:05 PM EST - 1 year ago

RenovoRx Highlights Key Leadership Promotions

RenovoRx CEO Issues Letter to Shareholders

Feb 6, 2024, 8:30 AM EST - 1 year ago

RenovoRx CEO Issues Letter to Shareholders

RenovoRx Closes $6.1 Million Private Placement

Jan 29, 2024, 8:30 AM EST - 1 year ago

RenovoRx Closes $6.1 Million Private Placement

RenovoRx Engages Oklahoma University (OU) Health as First Clinical Site in Preparation for the Pivotal Phase III CouGar Clinical Trial in Bile Duct Cancer

Dec 21, 2023, 8:30 AM EST - 1 year ago

RenovoRx Engages Oklahoma University (OU) Health as First Clinical Site in Preparation for the Pivotal Phase III CouGar Clinical Trial in Bile Duct Cancer

RenovoRx Announces Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting

Dec 19, 2023, 8:30 AM EST - 1 year ago

RenovoRx Announces Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting

RenovoRx Files New International Patent for Novel Targeted Combination Drug-Delivery Oncology Therapy Platform

Dec 13, 2023, 8:31 AM EST - 1 year ago

RenovoRx Files New International Patent for Novel Targeted Combination Drug-Delivery Oncology Therapy Platform

RenovoRx Expands Scientific Advisory Board with Appointment of Michel Ducreux, M.D., Ph.D.

Nov 16, 2023, 8:35 AM EST - 1 year ago

RenovoRx Expands Scientific Advisory Board with Appointment of Michel Ducreux, M.D., Ph.D.

RenovoRx Reports Third Quarter 2023 Financial Results and Operational Highlights

Nov 14, 2023, 8:30 AM EST - 1 year ago

RenovoRx Reports Third Quarter 2023 Financial Results and Operational Highlights

RenovoRx to Present at the ROTH MKM Healthcare Opportunities Conference on October 12, 2023

Oct 2, 2023, 8:30 AM EDT - 1 year ago

RenovoRx to Present at the ROTH MKM Healthcare Opportunities Conference on October 12, 2023

RenovoRx Reports Second Quarter 2023 Financial Results and Operational Highlights

Aug 17, 2023, 8:30 AM EDT - 1 year ago

RenovoRx Reports Second Quarter 2023 Financial Results and Operational Highlights

RenovoRx to Present at the 43rd Annual Canaccord Genuity Growth Conference

Jul 31, 2023, 8:30 AM EDT - 1 year ago

RenovoRx to Present at the 43rd Annual Canaccord Genuity Growth Conference

RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP™) Platform

Jul 20, 2023, 8:00 AM EDT - 1 year ago

RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP™) Platform

RenovoRx Announces New Positive Interim Phase III Data Demonstrating RenovoGem™ Delays Cancer Progression by Eight Months in Locally Advanced Pancreatic Cancer

Jun 29, 2023, 8:00 AM EDT - 1 year ago

RenovoRx Announces New Positive Interim Phase III Data Demonstrating RenovoGem™ Delays Cancer Progression by Eight Months in Locally Advanced Pancreatic Cancer

RenovoRx Appoints Margaret A. Tempero, M.D.

Jun 20, 2023, 8:30 AM EDT - 1 year ago

RenovoRx Appoints Margaret A. Tempero, M.D.

RenovoRx Announces ROTH Capital Key Opinion Leader (KOL) Webcast on June 15

Jun 12, 2023, 8:30 AM EDT - 2 years ago

RenovoRx Announces ROTH Capital Key Opinion Leader (KOL) Webcast on June 15